Stock Market & Financial Investment News

News Breaks January 8, 2013 07:13 EDT MRK Merck CEO: Bausch & Lomb deal 'worth thinking about,' Bloomberg reports In an interview at the JP Morgan Chase health conference, Merck (MRK) CEO Kenneth Frazier yesterday said that a potential acquisition of Bausch & Lomb would be "something worth thinking about," Bloomberg reports. Warbug Pincus, which owns Bausch & Lomb, is said to be seeking first-round bids by the end of the month and is seeking at least $10B for the business. Reference Link News For MRK From The Last 14 Days Check below for free stories on MRK the last two weeks. Sign up for a free trial to see the rest of the stories you've been missing. May 22, 2013 09:39 EDT MRK Active equity option families trading Subscribe for More Information 07:45 EDT MRK FDA Peripheral & Central Nervous System Drugs Advisory Committee holds a meeting Subscribe for More Information May 21, 2013 18:56 EDT MRK On The Fly: After Hours Movers Subscribe for More Information 17:03 EDT MRK Merck announces $5B share repurchase Subscribe for More Information 17:01 EDT MRK Merck announces $5B accelerated share repurchase Subscribe for More Information 07:44 EDT MRK Sachs Associates to host a forum Subscribe for More Information May 20, 2013 17:49 EDT MRK Merck sleep drug effective, dosages questioned, WSJ reports Subscribe for More Information 07:32 EDT MRK Society for Information Display / IHS to host a conference Display Week 2013 is being held in Vancouver, British Columbia on May 19-24. May 16, 2013 08:55 EDT MRK BofA/Merrill's pharmaceuticals analysts hold analyst/industry conference call Subscribe for More Information May 14, 2013 17:39 EDT MRK Moody's lowers Merck's guaranteed debt to A1 from Aa3; stable outlook Moody's Investors Service lowered the long-term ratings of Merck by one notch, including the guaranteed senior unsecured rating to A1 from Aa3 and the non-guaranteed senior unsecured rating to A2 from A1. This action concludes a review for downgrade initiated on May 1, 2013. At the same time, Moody's affirmed Merck's Prime-1 commercial paper rating. The rating outlook is stable. May 10, 2013 11:48 EDT MRK Drugmakers to face pressure on U.S. prices, Reuters says Subscribe for More Information 06:53 EDT MRK GlaxoSmithKline, Merck to discount cancer vaccine in poor nations, NY Times says Subscribe for More Information May 9, 2013 07:22 EDT MRK Merck awarded significant portion of UNICEF HPV vaccine tender Subscribe for More Information May 8, 2013 08:32 EDT MRK Merck says FDA accepts biologics license application for allergy tablet Merck announced that the Biologics License Application for its investigational ragweed pollen sublingual allergy immunotherapy tablet has been accepted for review by the U.S. Food and Drug Administration. The BLA for Merck’s investigational ragweed pollen sublingual allergy immunotherapy tablet is supported by five studies evaluating the efficacy and safety of the tablet in adults, 18 years of age or older, with ragweed induced allergic rhinitis. On March 27, Merck announced that the FDA had also accepted the BLA for its investigational Timothy grass pollen sublingual allergy immunotherapy tablet. Merck expects the FDA’s review for both to be completed in the first half of 2014. Sign up for a free trial to see the rest of the stories you've been missing.